November 7, 2019
Grifols expands in Latin America with start of production at new plant in Brazil
- With a capacity of more than 10 million blood collection bags annually, the more than 5,500-square-meter facility in Campo Largo, Brazil, will serve the Latin American region
- First Grifols manufacturing plant in Latin America is part of the company’s strategic regional growth plans.
Barcelona, Nov. 7, 2019 - Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and transfusion solutions, today announced the start of production at its new blood-collection systems plant in Campo Largo, Brazil.
The production line is already fulfilling local customer orders. With an annual capacity in excess of 10 million blood collection bags, the more than 5,500-square-meter plant is expected to gradually increase output to serve the broader Latin American region.
“The new plant will enable Grifols to expand its presence in Latin America,” said Daniel Fleta, Chief Industrial Officer. “We’re excited about the potential for growth as well as the flexibility and quicker time to market that comes with local production capabilities.”
Initially the plant will serve Brazil, expanding to include other countries in Latin America over the coming years, in line with market opportunities.
The Campo Largo plant is Grifols’ first manufacturing facility in Latin America, where the company established commercial operations in 1991. Currently Grifols commercializes a full range of products and solutions from its Bioscience, Diagnostic and Hospital business units in 23 countries across Latin America and the Caribbean.